Colokinetic effect of an insulin‐like peptide 5‐related agonist of the RXFP4 receptor

• Published in: Neurogastroenterology and motility Vol. 32; no. 5; pp. e13796 - n/a
• Main Authors: Diwakarla, Shanti, Bathgate, Ross A. D., Zhang, Xiaozhou, Hossain, Mohammed Akhter, Furness, John B.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.05.2020
• Subjects: Agonists; Animals; Antidiarrheals - administration & dosage; colokinetics; Colon; Colon - drug effects; Colon - physiology; Constipation; Constipation - chemically induced; Constipation - physiopathology; Disulfide bonds; Enteric nervous system; Gastrointestinal Motility - drug effects; Gastrointestinal Motility - physiology; HEK293 Cells; Humans; INSL5; Insulin; Loperamide - administration & dosage; Male; Mice, Inbred C57BL; Opioids; Peptide Hormones - chemistry; Peptides; Receptors, G-Protein-Coupled - agonists; Relaxin; RXFP4; constipation; RXFP4; colokinetics; INSL5
• ISSN: 1350-1925; 1365-2982
• DOI: 10.1111/nmo.13796

Background Insulin‐like peptide 5 (INSL5) is a hormone stored in colonic enteroendocrine cells that also contain the unrelated hormones, GLP‐1 and PYY. It acts at the relaxin family peptide 4, RXFP4, receptor. RXFP4 is expressed by enteric neurons in the colon, and it has been speculated that INSL5, through its action on enteric neurons, might be involved in the control of colonic contractions. Similar to insulin and relaxin, INSL5 consists of A and B peptide chains linked by three disulfide bonds, two between the chains and one intrinsic to the A chain. Because of its complex structure, it is difficult to synthesize and to prepare peptide analogues to investigate its roles. We have recently developed a potent simplified peptide analogue, INSL5‐A13 (INSL5 analogue 13). Methods In the present work, we have investigated the actions of INSL5‐A13 in mice. We investigated the ability of INSL5‐A13 to increase the speed of emptying of a bead from the colon, after expulsion had been slowed by the peripherally restricted opioid agonist, loperamide (1 mg/kg). Key Results INSL5‐A13 was a full agonist at the mouse RXFP4 expressed in HEK cells, with an EC50 of ~9 nmol/L. INSL5‐A13 caused an acceleration of colorectal bead propulsion in mice constipated by loperamide in the dose range 0.2 to 60 µg/kg, with an EC50 of ~6 µg/kg in vivo. It also accelerated bead propulsion in untreated mice. Bead expulsion was not accelerated in RXFP4−/− mice. Conclusion and Inferences Our data suggest that RXFP4 agonists could be useful in the treatment of constipation.